收费全文 | 20361篇 |
免费 | 1202篇 |
国内免费 | 154篇 |
耳鼻咽喉 | 231篇 |
儿科学 | 543篇 |
妇产科学 | 700篇 |
基础医学 | 2211篇 |
口腔科学 | 572篇 |
临床医学 | 1678篇 |
内科学 | 3951篇 |
皮肤病学 | 425篇 |
神经病学 | 987篇 |
特种医学 | 759篇 |
外国民族医学 | 11篇 |
外科学 | 3579篇 |
综合类 | 380篇 |
现状与发展 | 2篇 |
一般理论 | 12篇 |
预防医学 | 1720篇 |
眼科学 | 613篇 |
药学 | 1941篇 |
中国医学 | 163篇 |
肿瘤学 | 1239篇 |
2023年 | 240篇 |
2022年 | 640篇 |
2021年 | 1217篇 |
2020年 | 673篇 |
2019年 | 884篇 |
2018年 | 1111篇 |
2017年 | 660篇 |
2016年 | 701篇 |
2015年 | 702篇 |
2014年 | 971篇 |
2013年 | 1137篇 |
2012年 | 1643篇 |
2011年 | 1784篇 |
2010年 | 1001篇 |
2009年 | 741篇 |
2008年 | 1026篇 |
2007年 | 1038篇 |
2006年 | 949篇 |
2005年 | 886篇 |
2004年 | 764篇 |
2003年 | 700篇 |
2002年 | 628篇 |
2001年 | 153篇 |
2000年 | 120篇 |
1999年 | 107篇 |
1998年 | 80篇 |
1997年 | 77篇 |
1996年 | 75篇 |
1995年 | 67篇 |
1994年 | 62篇 |
1993年 | 52篇 |
1992年 | 65篇 |
1991年 | 68篇 |
1990年 | 63篇 |
1989年 | 58篇 |
1988年 | 61篇 |
1987年 | 51篇 |
1986年 | 41篇 |
1985年 | 41篇 |
1984年 | 43篇 |
1983年 | 46篇 |
1982年 | 37篇 |
1981年 | 25篇 |
1980年 | 21篇 |
1979年 | 15篇 |
1978年 | 16篇 |
1976年 | 17篇 |
1975年 | 17篇 |
1974年 | 17篇 |
1973年 | 19篇 |
Areas covered: This review was written after detailed search in PubMed, EMBASE, ISI web, SciELO, Scopus, and Cochrane Central Register databases (from 1970 to 2019). It summarized the reported ophthalmologic adverse effects of the currently available AEDs; their risks and possible pathogenic mechanisms. They include ocular motility dysfunctions, retinopathy, maculopathy, glaucoma, myopia, optic neuropathy, and impaired retinal vascular autoregulation. In general, ophthalmo-neuro- or retino-toxic adverse effects of AEDs are classified as type A (dose-dependent), type B (host-dependent or idiosyncratic) or type C which is due to the cumulative effect from long-term use.
Expert opinion: Ocular adverse effects of AEDs are rarely reviewed although some are frequent or may result in permanent blindness. Increasing knowledge of their incidence and improving understanding of their risks and pathogenic mechanisms are crucial for monitoring, prevention, and management of patients’ at risk. 相似文献
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献Background
Clear cell renal cell carcinoma (ccRCC) is known to occur across the adult lifetime traversing the spectrum of age-related organismal changes. Little is known as to how the aging process may affect the course of renal cell carcinoma (RCC) and the repertoire of genes involved.Methods
Using The Cancer Genome Atlas (n?=?436) and Cancer Genomics of the Kidney (n?=?89) datasets, we applied regression analysis to examine associations between patient age and gene expression profiles in ccRCC tumors and normal kidney tissues. Pathway enrichment analysis was performed to identify cellular process that is affected by aging in ccRCC. Moreover, connectivity mapping analysis was used to predict age-dependent response to drug treatments.Results
Our analysis revealed different age-dependent gene expression spectra in ccRCC and normal kidney tissues. These findings were significant and independently reproducible in both datasets examined. Age up-regulated genes, showing higher expression in older patients, were significantly enriched (false discovery rate <0.05) in normal tissues for pathways associated with immune response and extracellular matrix organization, whereas age up-regulated genes in tumors were enriched for metabolism and oxidation pathways. Strikingly, age down-regulated genes in normal cells were also enriched for metabolism and oxidation, while those in tumors were enriched for extracellular matrix organization. Further in silico analysis of potential drug targets predicted preferential efficacy of Phosphoinositide 3-kinase inhibitor or immunotherapy in association with age.Conclusion
We report on previously unrecognized associations between age and molecular underpinnings of RCC, including age-associated expression of genes implicated in RCC development or treatment. 相似文献Areas covered: The authors discuss basic information about CTCL and mogamulizumab’s mechanism of action. Then, the authors discuss the agent’s efficacy. Finally, the authors evaluate the safety of mogamulizumab in comparison to other agents available in CTCL.
Expert opinion: Mogamulizumab has been shown to be an effective and well tolerated therapy for patients with relapsed and refractory MF/SS with excellent activity in the circulating component of the disease. 相似文献
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)